StockData

Pacira BioSciences vs Ultragenyx Pharmaceutical

PCRX and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PCRX and RARE compare

Pacira BioSciences and Ultragenyx Pharmaceutical are about the same size, with market caps of $1.5B and $1.6B.

Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus 5.7% for Pacira BioSciences).

Pacira BioSciences keeps more of each dollar of sales as profit, with a net margin of 2.0% compared with −81.7% at Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 6 for Pacira BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPCRXRARE
Size and price
Market cap$1.5B$1.6B
Share price$36.48$16.70
Change, 1 year53.4%−49.5%
Change, 5 years−29.3%−78.2%
Beta (5Y)0.122.12
Employees8291,371
StockData Score
Total score69 (better)
Valuation score01 (better)
Growth score12 (better)
Performance score3 (better)1
Health score25 (better)
Dividend score00
Valuation
P/E104×–
P/S1.9× (better)2.3×
P/B2.2×–
EV/EBITDA14.9×–
P/FCF8.1×–
FCF yield12.3% (better)−29.7%
Fair value$28.47–
Margin of safety−28.1%–
Growth
Revenue growth (TTM)5.7%17.5% (better)
Revenue growth, 5Y average11.1%19.9% (better)
EPS growth, 5Y average−45.5%–
Profitability
Gross margin79.2%–
Operating margin2.7% (better)−73.6%
Net margin2.0% (better)−81.7%
FCF margin24.1% (better)−68.2%
Return on equity2.0%–
Return on invested capital3.0%–
Financial health
Debt / equity0.54–
Net debt / EBITDA1.07–
Interest coverage1.3×–
Current ratio5.04 (better)1.73
Altman Z-score2.44 (better)−5.26
Piotroski F-score8 (better)5
Dividends and buybacks
Buyback yield10.2%–
Shareholder yield10.2% (better)0.00%
Ownership
Held by institutions110%108%
Held by insiders6.1%4.0%
Insider net buying, 12 months−$2.4M (better)−$3.8M
Short interest, % of float8.9%25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.